SAGENT PHARMS
GenericsSAGENT PHARMS is a generic drug manufacturer focused on Infectious Disease, Dermatology, Oncology.
SAGENT PHARMS's Key Drugs
SAGENT PHARMS's core commercial portfolio centers on GLYDO, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
SAGENT PHARMS's Recent FDA Approvals
SAGENT PHARMS secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
SAGENT PHARMS's Therapeutic Areas
SAGENT PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SAGENT PHARMS's Top Competitors
SAGENT PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and COSETTE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SAGENT PHARMS Pipeline Snapshot
Active clinical trials for SAGENT PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GLYDO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1999-01-04
- Latest
- 2026-03-13
- Applications
- 79